17th Mar 2016 08:14
LONDON (Alliance News) - Investment company Imperial Innovations Group PLC on Thursday said portfolio company TopiVert Pharma Ltd has received positive phase 1 study results for its TOP1288 compound.
The study results for TopiVert, a clinical-stage biotechnology firm, demonstrated a rectal formulation of TOP1288, which inhibits key kinases linked to inflammation of the gastrointestinal tract and eye, had an excellent safety and tolerability profile in healthy volunteers.
TopiVert is now set to start a phase 2 study of an oral formulation of the compound in the second half of 2016.
Imperial Innovations holds a 31% stake in the company.
Imperial Innovations shares were up 0.4% to 416.47 pence on the news.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Imperial Innovations Group